Insider Selling: Protara Therapeutics, Inc. (NASDAQ:TARA) Insider Sells $96,144.72 in Stock

Protara Therapeutics, Inc. (NASDAQ:TARA) insider Jacqueline Zummo sold 21,224 shares of the stock in a transaction on Wednesday, March 26th. The shares were sold at an average price of $4.53, for a total transaction of $96,144.72. Following the sale, the insider now directly owns 98,861 shares of the company’s stock, valued at $447,840.33. The trade was a 17.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Protara Therapeutics Stock Performance

TARA stock opened at $4.58 on Monday. Protara Therapeutics, Inc. has a fifty-two week low of $1.60 and a fifty-two week high of $10.48. The company has a market capitalization of $168.39 million, a price-to-earnings ratio of -1.62 and a beta of 1.69. The business’s 50 day moving average price is $4.27 and its two-hundred day moving average price is $3.68.

Protara Therapeutics (NASDAQ:TARA) last issued its quarterly earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.09. Sell-side analysts forecast that Protara Therapeutics, Inc. will post -3.32 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Protara Therapeutics in a report on Friday, March 14th. They set an “overweight” rating for the company. Guggenheim reiterated a “buy” rating and issued a $20.00 price objective on shares of Protara Therapeutics in a report on Friday, December 6th. HC Wainwright restated a “buy” rating and set a $23.00 target price on shares of Protara Therapeutics in a report on Thursday, March 6th. Finally, Lifesci Capital began coverage on Protara Therapeutics in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $22.00 price target for the company. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Protara Therapeutics currently has an average rating of “Buy” and a consensus price target of $22.50.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. XTX Topco Ltd bought a new stake in Protara Therapeutics during the third quarter worth about $60,000. Geode Capital Management LLC boosted its position in shares of Protara Therapeutics by 21.0% in the 3rd quarter. Geode Capital Management LLC now owns 170,040 shares of the company’s stock worth $311,000 after purchasing an additional 29,514 shares in the last quarter. Bailard Inc. purchased a new stake in shares of Protara Therapeutics in the 4th quarter worth approximately $157,000. Oppenheimer & Co. Inc. increased its position in Protara Therapeutics by 12.4% during the 4th quarter. Oppenheimer & Co. Inc. now owns 201,426 shares of the company’s stock valued at $1,064,000 after buying an additional 22,301 shares in the last quarter. Finally, 5AM Venture Management LLC purchased a new position in Protara Therapeutics during the fourth quarter valued at $4,224,000. 38.13% of the stock is currently owned by institutional investors.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.